Organogenesis Inc.
Organogenesis has the skinny on replacement tissue. Flagship product Apligraf is a human skin substitute approved to treat diabetic foot ulcers and venous leg ulcers caused by poor circulation. Rejection-resistant Apligraf is bio-engineered using living skin cells and has been used to treat chronic open wounds in some 250,000 patients; the company is developing a next-generation version of the material (using its VCT technology) using all human components. In addition to Apligraf, Organogenesis offers a line of biomaterials used in a range of surgical procedures to seal or reconstruct soft tissue, and it also develops regenerative technologies in the area of cosmetic skin rejuvenation.
Contact Details
Office Address
Organogenesis Inc.
150 Dan Road
Canton, Massachusetts, USA 02021
Phone: (781) 575-0775
Fax: (781) 575-0440
Executives
President and CEO
Geoff MacKay
EVP, COO, and CFO
Gary S. Gillheeney Sr.